MARKET

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.190
0.000
0.00%
After Hours: 2.190 0 0.00% 17:24 07/10 EDT
OPEN
2.220
PREV CLOSE
2.190
HIGH
2.280
LOW
2.150
VOLUME
209.96K
TURNOVER
--
52 WEEK HIGH
4.230
52 WEEK LOW
1.230
MARKET CAP
148.43M
P/E (TTM)
-4.6408
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VTVT stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 6.00.

EPS

VTVT News

More
DVAX, IRBT among premarket gainers
Seeking Alpha - Article · 06/15 13:21
vTv Therapeutics' TTP399 successful in mid-stage type 1 diabetes study
Seeking Alpha - Article · 06/15 10:38
Early premarket gainers and losers
Seeking Alpha - Article · 06/15 09:54
vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at ADA Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients
vTv Therapeutics Inc.(NASDAQ: VTVT) on Saturday made two presentations at the American Diabetes Association's 80th Scientific Sessions.
Benzinga · 06/14 12:19
vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Associations Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients
GlobeNewswire · 06/13 16:00
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.
Benzinga · 06/07 17:43
Is vTv Therapeutics Inc (VTVT) A Good Stock To Buy?
Insider Monkey · 06/05 00:08
vTv Therapeutics to present full results from Phase 2 Simplici-T1 study of TTP399
Seeking Alpha - Article · 05/27 13:06

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About VTVT

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
More

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.